Eli Lilly and Company announced on April 20, 2026, that it has reached a definitive agreement to acquire Kelonia Therapeutics, a clinical-stage biotechnology firm specializing in genetic medicine. The transaction is structured with an initial cash payment of $3.25 billion and includes additional contingent consideration of up to $3.75 billion based on the achievement of specific development and commercial milestones. The total potential value of the acquisition reaches $7 billion, marking a significant expansion of Lilly’s footprint in the oncology and immunology sectors.
The acquisition centers on Kelonia’s proprietary in-vivo gene placement system, known as the iGPS platform. This technology is designed to deliver genetic payloads directly to specific cells within a patient's body, specifically targeting the advancement of Chimeric Antigen Receptor (CAR) T-cell therapies. Unlike traditional CAR-T methods that require extracting, modifying, and re-infusing a patient's immune cells—a process often referred to as ex-vivo—Kelonia’s approach seeks to enable the generation of CAR-T cells inside the patient. This method utilizes lentiviral vectors engineered to target specific cell types with high precision, potentially eliminating the need for toxic pre-conditioning chemotherapy.
Daniel Skovronsky, M.D., Ph.D., Eli Lilly’s Chief Scientific and Medical Officer, stated that the integration of Kelonia’s platform is intended to address the logistical and scalability challenges currently facing cell and gene therapies. By utilizing in-vivo delivery, the company aims to reduce the complexity of manufacturing and broaden patient access to treatments for various cancers and autoimmune diseases. The deal follows a period of increased investment by Lilly into its Institute for Genetic Medicine, which was established to centralize the company's efforts in RNA and DNA-based therapeutics.
Kevin Friedman, Ph.D., Chief Executive Officer of Kelonia Therapeutics, noted that the partnership with Lilly provides the necessary resources and global infrastructure to accelerate the clinical development of their lead candidates. Under the terms of the agreement, Kelonia will operate as a subsidiary within Lilly’s genetic medicine division, maintaining its primary research facilities in Boston. The boards of directors of both companies have approved the transaction, which remains subject to customary closing conditions and regulatory approvals under the Hart-Scott-Rodino Antitrust Improvements Act.
This acquisition represents one of the largest investments in the genetic medicine sector by Eli Lilly to date. It builds upon previous collaborations between the two entities, including a research partnership initiated in 2024 that focused on neurological applications. The companies expect the transaction to close by the end of the third quarter of 2026. Lilly confirmed that the upfront payment will be funded through available cash on hand and existing credit facilities, and the company does not anticipate the deal will alter its previously issued 2026 financial guidance.